Disease · MONDO_0019472

extranodal nasal NK/T cell lymphoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. extranodal nasal NK/T cell lymphoma. Diseases, record MONDO_0019472. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019472

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: extranodal nasal NK/T cell lymphoma; Open Targets
Open Targets ID: MONDO_0019472; Open Targets
Other names: Extranodal NK/T lymphoma-nasal, Extranodal NK/T-cell lymphoma, nasal type, NK/T-cell lymphoma, NKTCL, angiocentric T-cell lymphoma, lethal midline granuloma, nasal T/natural killer-cell lymphoma, nasal type Extranodal NK/T-cell lymphoma, reticulosis, malignant; Open Targets
Disease Ontology: DOID:0080797; Disease Ontology
NCI Thesaurus: C4684; NCI Thesaurus
Orphanet: ORPHA:86879; Orphanet
Highest stage of its drugs: Phase 3, for 4 of its 31 drugs, from ClinicalTrials.gov; Open Targets

Drugs31

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PEGASPARGASE	CHEMBL2108546	Enzyme	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
OXALIPLATIN	CHEMBL414804	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
SUGEMALIMAB	CHEMBL4594535	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Phase 2	ClinicalTrials.gov	6	6	6	Drugs and targets
ETOPOSIDE	CHEMBL44657	Small molecule	Phase 2	ClinicalTrials.gov	5	5	5	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
SINTILIMAB	CHEMBL4297829	Antibody	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
ASPARAGINASE	CHEMBL2108989	Enzyme	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
BORTEZOMIB	CHEMBL325041	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 31

See all 31 drugs

Targets79

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	4	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
TOP2A	DNA topoisomerase 2-alpha	3	DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor	Phase 2	https://conductscience.org/library/genes/7153	Drugs and targets
CD274	Programmed cell death 1 ligand 1	2	Programmed cell death 1 ligand 1 binding agent; Programmed cell death 1 ligand 1 inhibitor	Phase 3	https://conductscience.org/library/genes/29126	Drugs and targets
DNMT1	DNA (cytosine-5)-methyltransferase 1	2	DNA (cytosine-5)-methyltransferase 1 inhibitor	Phase 2	https://conductscience.org/library/genes/1786	Drugs and targets
DNMT3A	DNA (cytosine-5)-methyltransferase 3A	2	DNA (cytosine-5)-methyltransferase 3A inhibitor	Phase 2	https://conductscience.org/library/genes/1788	Drugs and targets
HDAC1	Histone deacetylase	2	Histone deacetylase 1 inhibitor; Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/3065	Drugs and targets
HDAC2	Histone deacetylase	2	Histone deacetylase 2 inhibitor; Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/3066	Drugs and targets
HDAC3	Histone deacetylase	2	Histone deacetylase 3 inhibitor; Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/8841	Drugs and targets
HDAC6	Histone deacetylase	2	Histone deacetylase 6 inhibitor; Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/10013	Drugs and targets
ADRM1	26S proteasome	1	26S proteasome inhibitor	Phase 2	https://conductscience.org/library/genes/11047	Drugs and targets

1 to 10 of 79

See all 79 targets

Trials30

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03228836	Efficacy and Safety Evaluation of IBI308 in Patients With Extranodal NK/T Cell Lymphoma Patients	Phase 2	28	2020-12-17	Effect of Drugs	SINTILIMAB	Its record names the disease	ClinicalTrials.gov
NCT03012620	Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types	Phase 2	334		Sarcoma, Ovarian Neoplasm, Central Nervous System Neoplasm, Thyroid Neoplasm, Carcinoma, Neuroendocrine, Neoplasms, Germ Cell and Embryonal, NK/T-cell Lymphoma	PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT05700448	Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma	Phase 3	150		Extranodal NK/T-cell Lymphoma	GEMCITABINE, OXALIPLATIN, PEGASPARGASE, SUGEMALIMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT03776279	A Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection in Relapsed/Refractory Peripheral T-cell Lymphoma and NK/T-cell Lymphoma	Phase 2	106		Relapsed or Refractory Peripheral T-cell and NK/T-cell Lymphoma	MITOXANTRONE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT06069830	PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma	Not applicable	89		NK-T-Cell Lymphoma, Extranodal	DEXAMETHASONE, ETOPOSIDE, PEGASPARGASE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00933673	New Combination Regimen of L-asparaginase, Dexamethasone, Ifosfamide, Cisplatin and Etoposide in NK/T-Cell Lymphoma	Phase 2	76		Lymphoma	ASPARAGINASE, CISPLATIN, DEXAMETHASONE, ETOPOSIDE, IFOSFAMIDE	Its record names the disease	ClinicalTrials.gov
NCT04511351	Radiotherapy Combined With GDP With or Without Chidamide in Stage I/II Extranodal Nasal NK/T-cell Lymphoma	Not applicable	76		Lymphoma	TUCIDINOSTAT	Its record names the disease	ClinicalTrials.gov
NCT03701022	PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma	Phase 2	61		NK/T-cell Lymphoma	RIVOCERANIB, SINTILIMAB	Its record names the disease	ClinicalTrials.gov
NCT00568607	Study on the Combination Regimen of Dexamethasone Ifosfamide Cisplatin Etoposide in Patients With NK/T Cell Lymphoma	Phase 2	60		Lymphoma	CISPLATIN, DEXAMETHASONE, ETOPOSIDE, IFOSFAMIDE	Its record names the disease	ClinicalTrials.gov
NCT05254899	A Study of Tislelizumab, Chemotherapy, and Radiation Therapy for Early-Stage High-Risk ENKTCL (CLCG-2102)	Phase 2	54		Extranodal NK-T-Cell Lymphoma, Early-stage, High-Risk Cancer	GEMCITABINE, OXALIPLATIN, PEGASPARGASE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 30

See all 30 trials

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials6

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
26210287	RESULT	1	PubMed
37828033	DERIVED	1	PubMed
37429302	DERIVED	1	PubMed
34702811	DERIVED	1	PubMed
26688485	DERIVED	1	PubMed
25355245	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0019472

GET https://conductscience.org/api/diseases/v1/MONDO_0019472/drugs?page=2

API reference For AI assistants